

06-19-2000



FORM 1595

2636- /01

101383945

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark OfficeRECORDATION FORM COVER SHEET
PATENTS ONLY

To the Honorable Commissioner of Patents and Trademarks. Please record the attached original documents or copy thereof.

1. Name of conveying party(ies):
Gilead Sciences, Inc.
NeXstar Pharmaceuticals, Inc.Additional name(s) of conveying
party(ies) attached? ☐ Yes ☒ No

2. Name and address of receiving party(ies):

Name Dr. Bruce Eaton

Internal Address: _____

Street Address: P.O. Box 19424

3. Name of Conveyance:

☒ Assignment ☐ Merger☐ Security Agreement ☐ Change of Name☐ Other _____Execution Date: March 10, 2000City BoulderState Colorado ZIP 80308Additional name(s) & addresses(es) attached?
☐ Yes ☒ No

4. Application number(s) or patent number(s):

If this document is being filed together with a new application, the execution date of the application is:

A. Patent Application No.(s) US95/11982; US96/08026
US97/02820; 08/464,107;
08/793,398; 09/157,601;
08/459,073; 08/816,709B. Patent No.(s) 5,723,289; 5,723,592; 5,789,160; 5,858,660;
5,719,273; 5,945,527; 5,659,069; 5,760,266Additional numbers attached? ☐ Yes ☒ No5. Name and address of party to whom correspondence
concerning document should be mailed:Name: Bart G. Newland, Esq.Internal Address: ROTHWELL, FIGG, ERNST & MANBECK, p.c.Street Address: 555 13th Street, N.W., Suite 701 East TowerCity: WashingtonState: D.C. Zip 200046. Total number of applications
and patents involved: 167. Total fee (37 CFR 3.41): . . . \$ 640.00☒ Enclosed☐ Authorized to be charged to deposit account

8. Deposit account number:

02-2135Attach duplicate copy of this page if paying by
deposit account

06/15/2000 DNGUYEN 00000251 5723289

DO NOT USE THIS SPACE

01 FC:581

640.00 OP

9. Statement and signature.

*To the best of my knowledge and belief, the foregoing information is true and correct and any attached copy is a
True copy of the original document.*Bart G. Newland, Reg. No. 31,282
Name of Person SigningBart G. Newland
SignatureMay 25, 2000
DateTotal number of pages including cover sheet, attachments and documents: 5PATENT
REEL: 010848 FRAME: 0295

ATTACHMENT D

ASSIGNMENT

WHEREAS, Gilead Sciences, Inc., a corporation duly organized and existing under the laws of the State of Delaware ("Gilead") and NeXstar Pharmaceuticals, Inc., a wholly owned subsidiary of Gilead duly organized and existing under the laws of the State of Delaware (collectively referred to as "Assignor") are the owners of certain inventions, including applications and Letters Patents of the United States therefor described in Exhibit I hereto;

AND WHEREAS, Bruce Eaton, an individual residing in the State of Colorado ("Assignee"), is desirous of conditionally acquiring the entire right, title, and interest in and to said inventions worldwide, including any foreign and domestic applications and patents therefor;

NOW, THEREFORE, for and in consideration of One Dollar (\$1.00) and other good and valuable consideration to Assignor in hand paid by Assignee, the receipt of which is hereby acknowledge, Assignor has sold, assigned, and transferred, and by these presents does hereby sell, assign, and transfer unto Assignee, its successors and assigns, Assignor's entire right, title, and interest in and to said inventions worldwide, and all applications for industrial property protection therefor, including, without limitation, any and all applications for patents, utility models, and designs, whether original, divisional, continuation, continuation-in-part, renewal, reissue, supplemental patent certificate, or the like thereof, now on file or hereinafter filed for said inventions anywhere in the world, together with the right to file any such applications and the right to claim for such applications the priority rights derived from said patent applications under the national intellectual property laws of any country or any other international intellectual property laws or agreements as may be applicable, and any industrial property protection, including, without limitation, patents, utility models, and designs, now or hereinafter granted for said inventions anywhere in the world, and any extensions, renewals, reissues, supplemental protection certificates, or the like thereof, and the right to sue for past, present, and future damages for infringement of any of said patents or patent applications;

AND WE HEREBY authorize and request any official of any State whose duty consists of issuing patents, or other evidence or forms of any industrial property protection on any aforesaid application, to issue same to said Assignee, its successors and assigns, in accordance herewith.

EXHIBIT I**EC PATENTS****Parallel SELEX**

<u>Serial #</u>	<u>File date</u>	<u>U.S. Patent number</u>	<u>Issue Date</u>	<u>Country</u>
08/309,245	09/20/94	5,723,289	3/3/98	US
08/462,389	06/05/95	5,723,592	3/3/98	US
08/463,101	6/5/95	5,789,160	8/4/98	US
08/618,700	3/20/96	5,858,660	1/12/99	US
08/464,107	6/5/95			US
08/793,398	2/24/97			US
09/157,601	9/21/98			US
36795/95	9/19/95			Australia
2,196,286	9/19/95			Canada
95 934 468	9/19/95			Europe
511062/96	9/19/95			Japan
701738/97	9/19/95			So. Korea
294127	9/19/95			New Zealand
334167	9/19/95			New Zealand
97106065	9/19/95			Russia
US95/11982	9/19/95			WIPO

Modified Nucleosides

<u>Serial #</u>	<u>File date</u>	<u>U.S. Patent number</u>	<u>Issue Date</u>	<u>Country</u>
08/458,421	6/2/95	5,719,273	2/17/98	US
08/952,338	11/4/97	5,945,527	8/31/99	US
08/459,073	6/2/95			US
61468/96	5/30/96			Australia
2,221,279	5/30/96			Canada
96 919 015.6	5/30/96			Europe
536652/96	5/30/96			Japan
US96/08026	5/30/96			WIPO

Methods for the Cyclotrimerization of Alkynes in Aqueous Solution

<u>Serial #</u>	<u>File date</u>	<u>U.S. Patent number</u>	<u>Issue Date</u>	<u>Country</u>
08/619,228	3/20/96	5,659,069	8/19/97	US
08/816,588	3/3/97	5,760,266	6/21/98	US
08/816,709	3/13/97			US
21351/97	2/25/97			Australia
2,248,352	2/25/97			Canada
97 906 737.8	2/25/97			Europe
533471/97	2/25/97			Japan
US97/02820	2/25/97			WIPO